This site is intended for Healthcare Professionals only

MHRA grants marketing authorisation for Maloff Protect

Clinical bookmark icon off

MHRA grants marketing authorisation for Maloff Protect

The MHRA has granted marketing authorisation for Glenmark Pharmaceuticcal’s Maloff Protect as a pharmacy only medicine.

Maloff Protect (atovaquone 250mg/proguanil 100mg) is an antimalarial medication for adults 18 years of age and over providing equivalent protection to prescription-only medication Malarone.

Up until now, atovaquone/proguanil antimalarials have only been available with a prescription. The launch of Maloff Protect will provide adult travellers with a more convenient, quick and easy way to access the antimalarial medication they need, and allow pharmacists to play a key role in antimalarial provision, says Glenmark.

In anticipation of launch, a full Risk Minimisation Materials (RMM) pack will be delivered to community pharmacies nationwide.

Glenmark Pharmaceuticals will also make available various training options (distinct from the RRM pack) to all pharmacists.

Maloff has an RRP (excluding VAT) of £39 (24 tablet pack) and £56.16 (36 tablet pack).

Copy Link

Clinical

Share: